Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,984 Million (Small Cap)
16.00
NA
3.68%
0.07
13.16%
2.06
Revenue and Profits:
Net Sales:
441 Million
(Quarterly Results - Sep 2025)
Net Profit:
73 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.88%
0%
5.88%
6 Months
5.36%
0%
5.36%
1 Year
28.02%
0%
28.02%
2 Years
47.19%
0%
47.19%
3 Years
-30.25%
0%
-30.25%
4 Years
6.03%
0%
6.03%
5 Years
16.81%
0%
16.81%
Well Lead Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.68%
EBIT Growth (5y)
6.84%
EBIT to Interest (avg)
22.65
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.63
Tax Ratio
12.97%
Dividend Payout Ratio
66.52%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.44%
ROE (avg)
11.37%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.12
EV to EBIT
14.93
EV to EBITDA
12.28
EV to Capital Employed
2.03
EV to Sales
2.63
PEG Ratio
1.19
Dividend Yield
3.72%
ROCE (Latest)
13.59%
ROE (Latest)
13.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
440.70
397.00
11.01%
Operating Profit (PBDIT) excl Other Income
82.70
93.10
-11.17%
Interest
2.10
6.40
-67.19%
Exceptional Items
0.80
-0.30
366.67%
Consolidate Net Profit
72.80
66.40
9.64%
Operating Profit Margin (Excl OI)
187.60%
204.00%
-1.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 11.01% vs 14.01% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 9.64% vs 9.57% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,499.80
1,378.10
8.83%
Operating Profit (PBDIT) excl Other Income
324.70
298.10
8.92%
Interest
12.80
9.60
33.33%
Exceptional Items
2.30
0.10
2,200.00%
Consolidate Net Profit
228.50
204.60
11.68%
Operating Profit Margin (Excl OI)
167.90%
164.00%
0.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.83% vs 2.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 11.68% vs 15.07% in Dec 2023
About Well Lead Medical Co., Ltd. 
Well Lead Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






